Evidence map›Paper›PMID 25174029›Full record

ArticleJournal of the National Cancer Institute. Monographs2014

Medical history, lifestyle, family history, and occupational risk factors for lymphoplasmacytic lymphoma/Waldenström's macroglobulinemia: the InterLymph Non-Hodgkin Lymphoma Subtypes Project.

Claire M Vajdic, Ola Landgren, Mary L McMaster, Susan L Slager, Angela Brooks-Wilson, Alex Smith, Anthony Staines, Ahmet Dogan, Stephen M Ansell, Joshua N Sampson and 2 more

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of the National Cancer Institute. Monographs, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed, 3 pooled it
3.0field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 3 syntheses or guidelines pooled it, 36 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Review
  5. Article
  6. Article
  7. Article
  8. Review
  9. Review
  10. Review
  11. Article
  12. Epidemiology of Non-Hodgkin's Lymphoma.Medical sciences (Basel, Switzerland) · 2021
    Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Waldenström macroglobulinemia: biology, genetics, and therapy.Blood and lymphatic cancer : targets and therapy · 2016
    Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 7 institutions in 5 countries.

Claire M VajdicPrince of Wales Clinical School, University of New South Wales, Sydney, Australia (CMV); Multiple Myeloma Section, Metabolism Branch (OL) and Division of Cancer Epidemiology and Genetics (MLM, JNS, LMM, MSL), National Cancer Institute, National Institutes of Health, Bethesda, MD; Department of Health Sciences Research, College of Medicine (SLS) and Division of Hematology (SMA), Mayo Clinic, Rochester, MN; Genome Sciences Centre, BC Cancer Agency, Vancouver, BC, Canada (AB-W); Department of Biomedical Physiology and Kinesiology, Simon Fraser University, Burnaby, BC, Canada (ABW); Epidemiology and Cancer Statistics Group, Department of Health Sciences, University of York, Heslington, York, UK (ASm); School of Nursing and Human Sciences, Dublin City University, Dublin, Leinster, Ireland (ASt); Department of Pathology, Memorial Sloan-Kettering Cancer Center, New York, NY (AD). claire.vajdic@unsw.edu.au.
Ola LandgrenPrince of Wales Clinical School, University of New South Wales, Sydney, Australia (CMV); Multiple Myeloma Section, Metabolism Branch (OL) and Division of Cancer Epidemiology and Genetics (MLM, JNS, LMM, MSL), National Cancer Institute, National Institutes of Health, Bethesda, MD; Department of Health Sciences Research, College of Medicine (SLS) and Division of Hematology (SMA), Mayo Clinic, Rochester, MN; Genome Sciences Centre, BC Cancer Agency, Vancouver, BC, Canada (AB-W); Department of Biomedical Physiology and Kinesiology, Simon Fraser University, Burnaby, BC, Canada (ABW); Epidemiology and Cancer Statistics Group, Department of Health Sciences, University of York, Heslington, York, UK (ASm); School of Nursing and Human Sciences, Dublin City University, Dublin, Leinster, Ireland (ASt); Department of Pathology, Memorial Sloan-Kettering Cancer Center, New York, NY (AD).
Mary L McMasterPrince of Wales Clinical School, University of New South Wales, Sydney, Australia (CMV); Multiple Myeloma Section, Metabolism Branch (OL) and Division of Cancer Epidemiology and Genetics (MLM, JNS, LMM, MSL), National Cancer Institute, National Institutes of Health, Bethesda, MD; Department of Health Sciences Research, College of Medicine (SLS) and Division of Hematology (SMA), Mayo Clinic, Rochester, MN; Genome Sciences Centre, BC Cancer Agency, Vancouver, BC, Canada (AB-W); Department of Biomedical Physiology and Kinesiology, Simon Fraser University, Burnaby, BC, Canada (ABW); Epidemiology and Cancer Statistics Group, Department of Health Sciences, University of York, Heslington, York, UK (ASm); School of Nursing and Human Sciences, Dublin City University, Dublin, Leinster, Ireland (ASt); Department of Pathology, Memorial Sloan-Kettering Cancer Center, New York, NY (AD).
Susan L SlagerPrince of Wales Clinical School, University of New South Wales, Sydney, Australia (CMV); Multiple Myeloma Section, Metabolism Branch (OL) and Division of Cancer Epidemiology and Genetics (MLM, JNS, LMM, MSL), National Cancer Institute, National Institutes of Health, Bethesda, MD; Department of Health Sciences Research, College of Medicine (SLS) and Division of Hematology (SMA), Mayo Clinic, Rochester, MN; Genome Sciences Centre, BC Cancer Agency, Vancouver, BC, Canada (AB-W); Department of Biomedical Physiology and Kinesiology, Simon Fraser University, Burnaby, BC, Canada (ABW); Epidemiology and Cancer Statistics Group, Department of Health Sciences, University of York, Heslington, York, UK (ASm); School of Nursing and Human Sciences, Dublin City University, Dublin, Leinster, Ireland (ASt); Department of Pathology, Memorial Sloan-Kettering Cancer Center, New York, NY (AD).
Angela Brooks-WilsonPrince of Wales Clinical School, University of New South Wales, Sydney, Australia (CMV); Multiple Myeloma Section, Metabolism Branch (OL) and Division of Cancer Epidemiology and Genetics (MLM, JNS, LMM, MSL), National Cancer Institute, National Institutes of Health, Bethesda, MD; Department of Health Sciences Research, College of Medicine (SLS) and Division of Hematology (SMA), Mayo Clinic, Rochester, MN; Genome Sciences Centre, BC Cancer Agency, Vancouver, BC, Canada (AB-W); Department of Biomedical Physiology and Kinesiology, Simon Fraser University, Burnaby, BC, Canada (ABW); Epidemiology and Cancer Statistics Group, Department of Health Sciences, University of York, Heslington, York, UK (ASm); School of Nursing and Human Sciences, Dublin City University, Dublin, Leinster, Ireland (ASt); Department of Pathology, Memorial Sloan-Kettering Cancer Center, New York, NY (AD).
Alex SmithPrince of Wales Clinical School, University of New South Wales, Sydney, Australia (CMV); Multiple Myeloma Section, Metabolism Branch (OL) and Division of Cancer Epidemiology and Genetics (MLM, JNS, LMM, MSL), National Cancer Institute, National Institutes of Health, Bethesda, MD; Department of Health Sciences Research, College of Medicine (SLS) and Division of Hematology (SMA), Mayo Clinic, Rochester, MN; Genome Sciences Centre, BC Cancer Agency, Vancouver, BC, Canada (AB-W); Department of Biomedical Physiology and Kinesiology, Simon Fraser University, Burnaby, BC, Canada (ABW); Epidemiology and Cancer Statistics Group, Department of Health Sciences, University of York, Heslington, York, UK (ASm); School of Nursing and Human Sciences, Dublin City University, Dublin, Leinster, Ireland (ASt); Department of Pathology, Memorial Sloan-Kettering Cancer Center, New York, NY (AD).
Anthony StainesPrince of Wales Clinical School, University of New South Wales, Sydney, Australia (CMV); Multiple Myeloma Section, Metabolism Branch (OL) and Division of Cancer Epidemiology and Genetics (MLM, JNS, LMM, MSL), National Cancer Institute, National Institutes of Health, Bethesda, MD; Department of Health Sciences Research, College of Medicine (SLS) and Division of Hematology (SMA), Mayo Clinic, Rochester, MN; Genome Sciences Centre, BC Cancer Agency, Vancouver, BC, Canada (AB-W); Department of Biomedical Physiology and Kinesiology, Simon Fraser University, Burnaby, BC, Canada (ABW); Epidemiology and Cancer Statistics Group, Department of Health Sciences, University of York, Heslington, York, UK (ASm); School of Nursing and Human Sciences, Dublin City University, Dublin, Leinster, Ireland (ASt); Department of Pathology, Memorial Sloan-Kettering Cancer Center, New York, NY (AD).
Ahmet DoganPrince of Wales Clinical School, University of New South Wales, Sydney, Australia (CMV); Multiple Myeloma Section, Metabolism Branch (OL) and Division of Cancer Epidemiology and Genetics (MLM, JNS, LMM, MSL), National Cancer Institute, National Institutes of Health, Bethesda, MD; Department of Health Sciences Research, College of Medicine (SLS) and Division of Hematology (SMA), Mayo Clinic, Rochester, MN; Genome Sciences Centre, BC Cancer Agency, Vancouver, BC, Canada (AB-W); Department of Biomedical Physiology and Kinesiology, Simon Fraser University, Burnaby, BC, Canada (ABW); Epidemiology and Cancer Statistics Group, Department of Health Sciences, University of York, Heslington, York, UK (ASm); School of Nursing and Human Sciences, Dublin City University, Dublin, Leinster, Ireland (ASt); Department of Pathology, Memorial Sloan-Kettering Cancer Center, New York, NY (AD).
Stephen M AnsellPrince of Wales Clinical School, University of New South Wales, Sydney, Australia (CMV); Multiple Myeloma Section, Metabolism Branch (OL) and Division of Cancer Epidemiology and Genetics (MLM, JNS, LMM, MSL), National Cancer Institute, National Institutes of Health, Bethesda, MD; Department of Health Sciences Research, College of Medicine (SLS) and Division of Hematology (SMA), Mayo Clinic, Rochester, MN; Genome Sciences Centre, BC Cancer Agency, Vancouver, BC, Canada (AB-W); Department of Biomedical Physiology and Kinesiology, Simon Fraser University, Burnaby, BC, Canada (ABW); Epidemiology and Cancer Statistics Group, Department of Health Sciences, University of York, Heslington, York, UK (ASm); School of Nursing and Human Sciences, Dublin City University, Dublin, Leinster, Ireland (ASt); Department of Pathology, Memorial Sloan-Kettering Cancer Center, New York, NY (AD).
Joshua N SampsonPrince of Wales Clinical School, University of New South Wales, Sydney, Australia (CMV); Multiple Myeloma Section, Metabolism Branch (OL) and Division of Cancer Epidemiology and Genetics (MLM, JNS, LMM, MSL), National Cancer Institute, National Institutes of Health, Bethesda, MD; Department of Health Sciences Research, College of Medicine (SLS) and Division of Hematology (SMA), Mayo Clinic, Rochester, MN; Genome Sciences Centre, BC Cancer Agency, Vancouver, BC, Canada (AB-W); Department of Biomedical Physiology and Kinesiology, Simon Fraser University, Burnaby, BC, Canada (ABW); Epidemiology and Cancer Statistics Group, Department of Health Sciences, University of York, Heslington, York, UK (ASm); School of Nursing and Human Sciences, Dublin City University, Dublin, Leinster, Ireland (ASt); Department of Pathology, Memorial Sloan-Kettering Cancer Center, New York, NY (AD).
Lindsay M MortonPrince of Wales Clinical School, University of New South Wales, Sydney, Australia (CMV); Multiple Myeloma Section, Metabolism Branch (OL) and Division of Cancer Epidemiology and Genetics (MLM, JNS, LMM, MSL), National Cancer Institute, National Institutes of Health, Bethesda, MD; Department of Health Sciences Research, College of Medicine (SLS) and Division of Hematology (SMA), Mayo Clinic, Rochester, MN; Genome Sciences Centre, BC Cancer Agency, Vancouver, BC, Canada (AB-W); Department of Biomedical Physiology and Kinesiology, Simon Fraser University, Burnaby, BC, Canada (ABW); Epidemiology and Cancer Statistics Group, Department of Health Sciences, University of York, Heslington, York, UK (ASm); School of Nursing and Human Sciences, Dublin City University, Dublin, Leinster, Ireland (ASt); Department of Pathology, Memorial Sloan-Kettering Cancer Center, New York, NY (AD).
Martha S LinetPrince of Wales Clinical School, University of New South Wales, Sydney, Australia (CMV); Multiple Myeloma Section, Metabolism Branch (OL) and Division of Cancer Epidemiology and Genetics (MLM, JNS, LMM, MSL), National Cancer Institute, National Institutes of Health, Bethesda, MD; Department of Health Sciences Research, College of Medicine (SLS) and Division of Hematology (SMA), Mayo Clinic, Rochester, MN; Genome Sciences Centre, BC Cancer Agency, Vancouver, BC, Canada (AB-W); Department of Biomedical Physiology and Kinesiology, Simon Fraser University, Burnaby, BC, Canada (ABW); Epidemiology and Cancer Statistics Group, Department of Health Sciences, University of York, Heslington, York, UK (ASm); School of Nursing and Human Sciences, Dublin City University, Dublin, Leinster, Ireland (ASt); Department of Pathology, Memorial Sloan-Kettering Cancer Center, New York, NY (AD).
BC Cancer Agency · CADublin City University · IEMayo Clinic in Florida · USNational Cancer Institute · USSimon Fraser University · CANational Institutes of Health · USUniversity of York · GB

Funding

The Role of Monocytes in non-Hodgkin LymphomaP50CA097274 · NCI · UNIVERSITY OF IOWA · PI WEINER, GEORGE J. · 2002 to 2021
$45.7M
Mayo Clinic Center for Translational Science ActivitiesUL1TR000135 · NCATS · MAYO CLINIC ROCHESTER · PI KHOSLA, SUNDEEP · 2012 to 2015
$41.2M
UNIVERSITY OF ROCHESTER'S RESEARCH ASSOCIATE ORGANIZATIONUL1RR024160 · NCRR · UNIVERSITY OF ROCHESTER · PI PEARSON, THOMAS ARTHUR · 2006 to 2011
$38.7M
SPORE in LymphomaP50CA130805 · NCI · UNIVERSITY OF ROCHESTER · PI FISHER, RICHARD I · 2008 to 2012
$11.7M
Multidisciplinary Studies of LymphomaZIACP010170 · NCI · DIVISION OF CANCER EPIDEMIOLOGY AND GENETICS · PI MORTON, LINDSAY · 2009 to 2025
$10.7M
Genetic Epidemiology of Chronic Lymphocytic LeukemiaU01CA118444 · NCI · MAYO CLINIC ROCHESTER · PI SLAGER, SUSAN L · 2006 to 2015
$7.1M
Molecular Epidemiology of non Hodgkin's LymphomaR01CA087014 · NCI · UNIVERSITY OF CALIFORNIA SAN FRANCISCO · PI HOLLY, ELIZABETH A. · 2001 to 2005
$6.7M
Molecular Epidemiology of NHL and CLLR01CA092153 · NCI · MAYO CLINIC ROCHESTER · PI CERHAN, JAMES R · 2003 to 2012
$6.7M
SURVEILLANCE, EPIDEMIOLOGY, AND END RESULTS--SEERN01PC065064 · PC · WAYNE STATE UNIVERSITY · PI WEISS, LINDA K · 1996 to 2000
$4.5M
SURVEILLANCE EPIDEMIOLOGY &END RESULTS PROGRAMN01PC067008 · PC · UNIVERSITY OF IOWA · PI LYNCH, CHARLES · 1996 to 2000
$3.8M
SURVEILLANCE EPIDEMIOLOGY &END RESULTS PROGRAMN01PC067009 · PC · FRED HUTCHINSON CANCER RESEARCH CENTER · PI THOMAS, DAVID B · 1996 to 2000
$3.0M
A Genome-Wide Association Study of Non-Hodgkin LymphomaR01CA122663 · NCI · UNIVERSITY OF CALIFORNIA BERKELEY · PI SKIBOLA, CHRISTINE F. · 2006 to 2010
$2.7M
CIHRIntramural NIH HHSNCATS NIH HHS UL1 TR000135NCI NIH HHS 5R01 CA69669-02NCI NIH HHS CA143947NCI NIH HHS CA150037NCI NIH HHS CA165923NCI NIH HHS CA51086NCI NIH HHS CA62006NCI NIH HHS K23 CA102216NCI NIH HHS N01 CO012400NCI NIH HHS N01-CO-12400NCI NIH HHS N01-CP-95618NCI NIH HHS N01-CP-ES-11027NCI NIH HHS N01 PC065064NCI NIH HHS N01 PC067008NCI NIH HHS N01 PC067009NCI NIH HHS N01 PC067010NCI NIH HHS N01-PC-65064NCI NIH HHS N01-PC-67008NCI NIH HHS N01-PC-67009NCI NIH HHS N01-PC-67010NCI NIH HHS N02-PC-71105NCI NIH HHS P50 CA097274NCI NIH HHS P50 CA130805NCI NIH HHS P50 CA97274NCI NIH HHS R01 CA045614NCI NIH HHS R01 CA051086NCI NIH HHS R01 CA062006NCI NIH HHS R01 CA087014NCI NIH HHS R01CA087014NCI NIH HHS R01 CA092153NCI NIH HHS R01 CA100555NCI NIH HHS R01CA100555NCI NIH HHS R01 CA104682NCI NIH HHS R01CA104682NCI NIH HHS R01 CA122663NCI NIH HHS R01CA122663NCI NIH HHS R01 CA14690NCI NIH HHS R01 CA154643NCI NIH HHS R01CA154643-01A1NCI NIH HHS R01CA45614NCI NIH HHS R01CA50850NCI NIH HHS R01 CA92153NCI NIH HHS R01CA92153-S1NCI NIH HHS R03CA125831NCI NIH HHS R03 CA132153NCI NIH HHS R03CA132153NCI NIH HHS R03 CA143947NCI NIH HHS R03 CA150037NCI NIH HHS R21 CA165923NCI NIH HHS U01 CA118444NCRR NIH HHS UL 1 RR024160NHLBI NIH HHS T32 HL007152NIAID NIH HHS R01 AI050850NIDA NIH HHS R01 DA014690NIDCD NIH HHS R01 DC014690NIEHS NIH HHS K22 ES011027
6 · The paper itself

Abstract

backgroundLymphoplasmacytic lymphoma/Waldenström's macroglobulinemia (LPL/WM), a rare non-Hodgkin lymphoma subtype, shows strong familial aggregation and a positive association with chronic immune stimulation, but evidence regarding other risk factors is very limited.

methodsThe International Lymphoma Epidemiology Consortium (InterLymph) pooled data from 11 predominantly population-based case-control studies from North America, Europe, and Australia to examine medical history, lifestyle, family history, and occupational risk factors for LPL/WM. Age-, sex-, race/ethnicity-, and study-adjusted odds ratios (ORs) and 95% confidence intervals (CIs) were estimated using logistic regression for a total of 374 LPL/WM cases and 23 096 controls.

resultsIn multivariate analysis including all putative risk factors, LPL/WM risk was associated with history of Sjögren's syndrome (OR = 14.0, 95% CI = 3.60 to 54.6), systemic lupus erythematosus (OR = 8.23, 95% CI = 2.69 to 25.2), hay fever (OR = 0.73, 95% CI = 0.54 to 0.99), positive hepatitis C serology (OR = 2.51, 95% CI = 1.03 to 6.17), hematologic malignancy in a first-degree relative (OR = 1.64, 95% CI = 1.02 to 2.64), adult weight (OR = 0.61, 95% CI = 0.44 to 0.85 for highest vs. lowest quartile), duration of cigarette smoking (OR = 1.46, 95% CI = 1.04 to 2.05 for ≥ 40 years vs. nonsmokers), and occupation as a medical doctor (OR = 5.54, 95% CI = 2.19 to 14.0). There was no association with other medical conditions, lifestyle factors, or occupations.

conclusionsThis pooled analysis confirmed associations with immune conditions and family history of hematologic malignancy, and identified new associations with hay fever, weight, smoking, and occupation, and no association with other lifestyle factors. These findings offer clues to LPL/WM biology and prevention.

Indexed as

Life StyleOccupational ExposureAdultAgedAged, 80 and overAustraliaCase-Control StudiesComorbidityEuropeFemaleHumansMaleMiddle AgedNorth AmericaRisk FactorsWaldenstrom Macroglobulinemia

Identifiers

PMID25174029
PMCPMC4155457
OpenAlexW2068483646

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.